Development of Tazobactam/Piperacillin Optimal Individualized Dose and Route for Maximize the Effects in Empiric Therapy.
Not Applicable
Recruiting
- Conditions
- One or more of the following infections: sepsis, pneumonia, peritonitis, intra-abdominal abscess, cholecystitis, and cholangitis
- Registration Number
- JPRN-UMIN000050335
- Lead Sponsor
- Yamaguchi University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
Not provided
Exclusion Criteria
Patients on dialysis Patients scheduled for less than 3 days of treatment with Tazobactam/Piperacillin Other patients deemed inappropriate by the attending physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method